Emergent BioSolutions (EBS) Stock Price, Quote, News & History | Benzinga

Emergent BioSolutions Inc (EBS) Stock Price, Quote, News & History

EBSNYSE

Trade with Public

Trade with Public

$4.49

-0.06-1.32%

At close: Aug 12, 5:00 PM EST

$4.49

-0.0582-1.28%

Pre-Market: 6:21 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$4.49

Volume / Avg.

23.00 / 992.69K

Day Range

- - -

52 Wk Range

4.36 - 14.06

Market Cap

$232.68M

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

18

Short Interest

19.67%

Days to Cover

17.65

Recent Emergent BioSolutions Inc. News

Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED)

Avi Kapoor

Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results

U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares up 21% on Q4 earnings.

Avi Kapoor

Dow Dips Over 600 Points; US Producer Prices Increase In January

US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in January.

Avi Kapoor

Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Emergent BioSolutions Wins FDA Approval For New Narcan Multipacks To Expand Overdose Access

Emergent BioSolutions Inc. (EBS) stock rose Friday as FDA approved new multipack configurations of over-the-counter NARCAN Nasal Spray.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

97.70M

Investing Cash Flow (TTM)

-62.00M

Financing Cash Flow (TTM)

-165.60M

Free Cash Flow (TTM)

85.90M

Capital Expenditure (TTM)

-11.80M

Net Change in Cash (TTM)

-129.90M

Analyst Trends and Forecast

1

Mar

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$672.32M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

0.33

PB Ratio (TTM)

0.67

Earnings Yield % (TTM)

-75.95%

Earnings Yield % (FWD)

-44.10%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

2.83

Book Value / Share

$6.66

Company Debt

Total Debt

$581.80M

LT Debt

$581.80M

LT Debt Issuance (TTM)

$145.50M

LT Debt Repayment (TTM)

-$258.70M

Total Cash

$139.70M

Debt to Equity

1.70

Issuance of Debt (TTM)

-$113.20M

Repayment of Debt (TTM)

-$258.70M

Key Statistics

Open

-

Close

$4.49

Volume / Avg.

23.00 / 992.69K

Day Range

- - -

52 Wk Range

4.36 - 14.06

Market Cap

$232.68M

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

18

Short Interest

19.67%

Days to Cover

17.65

About

Sector

Health Care

Industry

Biotechnology

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal S...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Emergent BioSolutions (EBS) stock?

A

You can purchase shares of Emergent BioSolutions (NYSE:EBS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Emergent BioSolutions (EBS) competitors?

A

Other companies in Emergent BioSolutions’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Emergent BioSolutions (EBS) stock?

A

Emergent BioSolutions has a consensus price target of $13.50.

Q

What is the current price for Emergent BioSolutions (EBS)?

A

The stock price for Emergent BioSolutions (NYSE: EBS) is $4.4918 last updated August 13, 2026 at 6:40 PM EDT.

Q

Does Emergent BioSolutions (EBS) pay a dividend?

A

There are no upcoming dividends for Emergent BioSolutions.

Q

When is Emergent BioSolutions (NYSE:EBS) reporting earnings?

A

Emergent BioSolutions does not have any upcoming earnings scheduled.

Q

Is Emergent BioSolutions (EBS) going to split?

A

There is no upcoming split for Emergent BioSolutions.

Q

What sector and industry does Emergent BioSolutions (EBS) operate in?

A

Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.